Status:
COMPLETED
COVID-19 Vaccine and Ovarian Reserve
Lead Sponsor:
Sheba Medical Center
Conditions:
Fertility Issues
Vaccine Adverse Reaction
Eligibility:
FEMALE
11-42 years
Brief Summary
As Israel is the first country to widely vaccinate its population using the mRNA vaccine against COVID-19, evaluating its influence on ovarian reserve is essential .
Detailed Description
Introduction: Although there is as yet no scientific evidence that a SARS-CoV-2 virus infection could have negative effects on fertility, currently the possibility that the virus could affect sperm f...
Eligibility Criteria
Inclusion
- Age 11-42
- No previous exposure to Covid-19 vaccine (first or second dose)
- No known past Covid-19 infection
Exclusion
- Premature ovarian failure
- Pregnancy
- Fertility treatment
- Past Covid-19 infection
Key Trial Info
Start Date :
February 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 1 2023
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04748172
Start Date
February 1 2021
End Date
June 1 2023
Last Update
June 22 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sheba Medical Center
Ramat Gan, Israel, 56506